Source:http://linkedlifedata.com/resource/pubmed/id/18973272
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2008-11-27
|
pubmed:abstractText |
Epstein-Barr Virus (EBV)-associated immunoblastic lymphoma occurs in immunocompromised patients such as those with AIDS or transplant recipients after primary EBV infection or reactivation of a preexisting latent EBV infection. In the present study, we evaluated the effect of ritonavir, an HIV protease inhibitor, on EBV-positive lymphoblastoid B cells in vitro and in mice model. We found that it induced cell-cycle arrest at G1-phase and apoptosis through down-regulation of cell-cycle gene cyclin D2 and antiapoptotic gene survivin. Furthermore, ritonavir suppressed transcriptional activation of NF-kappaB in these cells. Ritonavir efficiently prevented growth and infiltration of lymphoma cells in various organs of NOD/SCID/gammacnull mice at the same dose used for treatment of patients with AIDS. Our results indicate that ritonavir targets NF-kappaB activated in tumor cells and shows anti-tumor effects. These data also suggest that this compound may have promise for treatment or prevention of EBV-associated lymphoproliferative diseases that occur in immunocompromised patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1097-0215
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright (c) 2008 Wiley-Liss, Inc.
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
124
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
622-9
|
pubmed:meshHeading |
pubmed-meshheading:18973272-Animals,
pubmed-meshheading:18973272-Apoptosis,
pubmed-meshheading:18973272-Blotting, Western,
pubmed-meshheading:18973272-Cell Cycle,
pubmed-meshheading:18973272-Cell Movement,
pubmed-meshheading:18973272-Cell Proliferation,
pubmed-meshheading:18973272-Electrophoretic Mobility Shift Assay,
pubmed-meshheading:18973272-Epstein-Barr Virus Infections,
pubmed-meshheading:18973272-HIV Protease Inhibitors,
pubmed-meshheading:18973272-Herpesvirus 4, Human,
pubmed-meshheading:18973272-Humans,
pubmed-meshheading:18973272-In Situ Hybridization, Fluorescence,
pubmed-meshheading:18973272-Lymphoma, B-Cell,
pubmed-meshheading:18973272-Mice,
pubmed-meshheading:18973272-NF-kappa B,
pubmed-meshheading:18973272-Polymerase Chain Reaction,
pubmed-meshheading:18973272-Ritonavir,
pubmed-meshheading:18973272-Transcriptional Activation,
pubmed-meshheading:18973272-Xenograft Model Antitumor Assays
|
pubmed:year |
2009
|
pubmed:articleTitle |
An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells.
|
pubmed:affiliation |
Department of Molecular Virology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|